162 related articles for article (PubMed ID: 25256058)
1. PRRT: Defining the paradigm shift to achieve standardization and individualization.
Bodei L; Kidd M; Baum RP; Modlin IM
J Nucl Med; 2014 Nov; 55(11):1753-6. PubMed ID: 25256058
[TBL] [Abstract][Full Text] [Related]
2. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
4. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
5. How We Do It: A Multidisciplinary Approach to
Burkett BJ; Dundar A; Young JR; Packard AT; Johnson GB; Halfdanarson TR; Eiring RA; Gansen DN; Patton CM; Kendi AT
Radiology; 2021 Feb; 298(2):261-274. PubMed ID: 33231532
[TBL] [Abstract][Full Text] [Related]
6. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
7. The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
Hindié E; Baudin E; Hicks RJ; Taïeb D
J Nucl Med; 2023 Apr; 64(4):522-524. PubMed ID: 36604184
[No Abstract] [Full Text] [Related]
8. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
Ramage J; Naraev BG; Halfdanarson TR
Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
[No Abstract] [Full Text] [Related]
9. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
10. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
[No Abstract] [Full Text] [Related]
11. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Bushnell DL; Bodeker KL
Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
[TBL] [Abstract][Full Text] [Related]
12. Personalized
Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
[TBL] [Abstract][Full Text] [Related]
13. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
14. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
15. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
16. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
Minczeles NS; Hofland J; de Herder WW; Brabander T
Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105
[TBL] [Abstract][Full Text] [Related]
17. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
18. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
19. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
Bodei L; Kidd M; Prasad V; Modlin IM
Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]